Gapping up
In reaction to strong earnings/guidance: CEVA +11.3%, CLX +6%, EL +5%, DO +4.6%, CAH +3.1%, SYY +0.8%
M&A news: DYAX +33.7% (to be acquired by Shire (SHPG) for $37.30/share), CTCT +21.1% (Constant Contact to be acquired by Endurance International Group (EIGI) for $32/share), CAG +4.8% (to acquire ConAgra Foods' (CAG) private brands operations for $2.7 billion; expects dilution in year one, and accretion thereafter; preannounces Q3)
Other news: UNXL +50.5% (reports receiving a pre-production order, from a major PC OEM for a 10 inch tablet product), ACAD +9.1% (announces FDA Priority Review of NUPLAZID (Pimavanserin) New Drug Application for Parkinson's Disease Psychosis), SORL +5.2% (confirms non-binding proposal to be acquired for $2.84 per share), VRX +4.5% (continuing to rebound after recent decline), NEO +3.4% (General Electric (GE) discloses 7.7% active stake in 13D filing ), FIT +2.9% (favorable commentary on Friday's Mad Money), WYNN +2.6% (Macau Oct gaming revs released), BLDP +2.6% (signs agreement with Tangshan Railway Vehicle Co for development of a new fuel cell module; valued at $3 mln), MGM +2.4% (Macau Oct gaming revs released), PFE +0.7% (Pfizer (PFE) and AGN plan to secure deal this month, according to Bloomberg )
Analyst comments: WEN +3.7% (upgraded to Outperform at RBC Capital Mkts), RAX +2.5% (upgraded to Buy from Neutral at BofA/Merrill ), MGM +2.4% (upgraded to Buy from Neutral at UBS), ABBV +2.4% (upgraded to Overweight from Equal-Weight at Morgan Stanley), RBS +2.1% (upgraded to Outperform from Neutral at Exane BNP Paribas), KEY +1.8% (upgraded to Outperform from Mkt Perform at Keefe Bruyette
)
In reaction to strong earnings/guidance: CEVA +11.3%, CLX +6%, EL +5%, DO +4.6%, CAH +3.1%, SYY +0.8%
M&A news: DYAX +33.7% (to be acquired by Shire (SHPG) for $37.30/share), CTCT +21.1% (Constant Contact to be acquired by Endurance International Group (EIGI) for $32/share), CAG +4.8% (to acquire ConAgra Foods' (CAG) private brands operations for $2.7 billion; expects dilution in year one, and accretion thereafter; preannounces Q3)
Other news: UNXL +50.5% (reports receiving a pre-production order, from a major PC OEM for a 10 inch tablet product), ACAD +9.1% (announces FDA Priority Review of NUPLAZID (Pimavanserin) New Drug Application for Parkinson's Disease Psychosis), SORL +5.2% (confirms non-binding proposal to be acquired for $2.84 per share), VRX +4.5% (continuing to rebound after recent decline), NEO +3.4% (General Electric (GE) discloses 7.7% active stake in 13D filing ), FIT +2.9% (favorable commentary on Friday's Mad Money), WYNN +2.6% (Macau Oct gaming revs released), BLDP +2.6% (signs agreement with Tangshan Railway Vehicle Co for development of a new fuel cell module; valued at $3 mln), MGM +2.4% (Macau Oct gaming revs released), PFE +0.7% (Pfizer (PFE) and AGN plan to secure deal this month, according to Bloomberg )
Analyst comments: WEN +3.7% (upgraded to Outperform at RBC Capital Mkts), RAX +2.5% (upgraded to Buy from Neutral at BofA/Merrill ), MGM +2.4% (upgraded to Buy from Neutral at UBS), ABBV +2.4% (upgraded to Overweight from Equal-Weight at Morgan Stanley), RBS +2.1% (upgraded to Outperform from Neutral at Exane BNP Paribas), KEY +1.8% (upgraded to Outperform from Mkt Perform at Keefe Bruyette
)